本系统评价研究了经口机器人声门上喉切除术 (TORS-SGL) 治疗 cT1-T3 喉鳞状细胞癌 (LSCC) 的手术、功能和肿瘤学结果。两位研究人员对 PubMed、Scopus 和 Cochrane 图书馆的研究进行了更新的系统评价使用 PRISMA 语句研究 TORS-SGL 的手术、功能和肿瘤学结果。偏倚分析以未成年人为对象进行。共纳入 21 项研究，涉及 896 名患者。 TORS-SGL 主要针对 cT1 (39.1%)、cT2 (46.9%) 和一些选定的 cT3 (7.7%) LSCC 进行。 10.8% 的病例手术切缘呈阳性。平均住院时间为 8.6 天。出血 (6.3%)、肺炎 (5.5%) 和误吸 (1.7%) 是主要并发症。 10.6% 的病例手术切缘呈阳性。饲管、临时气管切开术和确定性经皮胃造口术的发生率分别为 65.6%、19.7% 和 5.2%。平均 7.2 天后重新开始口服饮食。 TORS-SGL 的 5 年 OS 和 DFS 估计为 78.3% 和 91.7%，5 年局部无复发生存率和淋巴结无复发生存率分别为 90.8% 和 86.6%。 TORS-SGL 是一种安全有效的 cT1-T3 SGL 手术方法。功能和手术结果与 TOLM-SGL 相当。 TORS-SGL 的肿瘤学结果可能优于 TOLM 和开放式 SGL，但需要进一步的大型队列对照研究才能得出可靠的结论。版权所有 © 2024 Elsevier Ltd。保留所有权利。

This systematic review investigated the surgical, functional, and oncological outcomes of transoral robotic supraglottic laryngectomy (TORS-SGL) for cT1-T3 laryngeal squamous cell carcinoma (LSCC).Two investigators conducted an updated PubMed, Scopus, and Cochrane Library systematic review for studies investigating the surgical, functional, and oncological outcomes of TORS-SGL using the PRISMA statements. The bias analysis was conducted with the MINORS.Twenty-one studies were included, accounting for 896 patients. TORS-SGL was primarily performed for cT1 (39.1 %), cT2 (46.9 %), and some selected cT3 (7.7 %) LSCCs. Surgical margins were positive in 10.8 % of cases. The mean hospital stay was 8.6 days. Hemorrhage (6.3 %), pneumonia (5.5 %), and aspiration (1.7 %) are the primary complications. The surgical margins were positive in 10.6 % of cases. Feeding tubes, temporary tracheotomy, and definitive percutaneous gastrostomy are found in 65.6 %, 19.7 %, and 5.2 % of patients, respectively. The oral diet is restarted after a mean of 7.2 days. The 5-year OS and DFS of TORS-SGL were estimated to be 78.3 %, and 91.7 %, with 5-year local-relapse-free survival and nodal-relapse-free survival of 90.8 %, and 86.6 %, respectively.The TORS-SGL is a safe, and effective surgical approach for cT1-T3 SGL. The functional and surgical outcomes appear comparable with TOLM-SGL. The oncological outcomes of TORS-SGL could be better than TOLM and open SGLs, but further large cohort-controlled studies are needed to draw reliable conclusions.Copyright © 2024 Elsevier Ltd. All rights reserved.